Compounded medications prepared by pharmacists or physicians have been used extensively throughout history as a mainstay of therapeutics. Over the past half-century – with the increasing focus on evidence based treatment the use of compounded medications substantially decreased. However, in some therapeutic areas, such as menopause, use of compounded medications continues.

The continuation of use of compounded medications represents a challenge to the USFDA because the standard evaluations of benefit and risk are not required.
To gain guidance in this concern the FDA asked the National Academies of Sciences, Engineering and Medicine to form a consensus committee to characterize the clinical utility of compounded bioidentical hormone therapy.
The committee was chaired by Dr. Donald Mattison the Chief Medical Officer of Risk Sciences International and composed of a dozen clinicians and scientists who worked together over the course of 1.5 years to pull the literature on risk-benefit, and clinical utility of compounded bioidentical hormone therapy. The publication can be downloaded here.
The committee concluded (Conclusion 9.1) that there is insufficient evidence to support the overall clinical utility of compounded bioidentical hormone therapy as treatment for menopause and male hypogonadism symptoms.
Posted in RSI News
More RSI News
RSI hosts Mitacs intern
Risk Sciences International will host Abdallah Alami as an intern in statistics with support from the Mitacs Accelerate program. This unique university-industry program supports interns at…
Read News ItemCountry Foods Forum
Leading up to February 11 and 12, 2020, Risk Sciences International had the privilege of assisting Health Canada in its organization of the Country Foods…
Read News ItemWorkshop on Evidence Integration December 5-6, 2019
Risk Sciences International is organizing a two day Workshop on Evidence Integration in support of human health risk assessment in collaboration with the McLaughlin Centre…
Read News ItemRSI wins 2019 Consulting Engineers of Ontario Award of Merit
Risk Sciences International (RSI), as members of a consulting team with Stantec, along with the Ontario First Nations Technical Services Corporation (OFNTSC), has won an Award of Merit from the…
Read News Item